Novel insights into causal effects of serum lipids, lipid metabolites, and lipid-modifying targets on the risk of intracerebral aneurysm

被引:0
|
作者
Qiu, Youjia [1 ]
Song, Bingyi [1 ]
Yin, Ziqian [1 ]
Wang, Menghan [1 ]
Tao, Yuchen [1 ]
Xie, Minjia [1 ]
Duan, Aojie [1 ]
Chen, Zhouqing [1 ]
Si, Ke [2 ]
Wang, Zhong [1 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou 215006, Jiangsu, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Cardiac Surg, Suzhou 215006, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Lipid; metabolites; statins; aneurysm; phenotype; Mendelian randomization; UNRUPTURED INTRACRANIAL ANEURYSMS; INDUCED CEREBRAL ANEURYSMS; MENDELIAN RANDOMIZATION; PREVENTION; STATINS; RUPTURE; GROWTH; SEX; AGE;
D O I
10.1177/23969873241265019
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Different serum lipid and lipid-lowering agents are reported to be related to the occurrence of intracerebral aneurysm (IA). However, the causal relationship between them requires further investigation. Patients and methods: Mendelian randomization (MR) analysis was performed on IA and its subtypes by using instrumental variants associated with six serum lipids, 249 lipid metabolic traits, and 10 lipid-lowering agents that were extracted from the largest genome-wide association study. Phenome-wide MR analyses were conducted to identify potential phenotypes associated with significant lipid-lowering agents. Results: After multiple comparison adjustments (p < 0.0083), genetically proxied triglyceride (TG) (odds ratio [OR] 1.25, 95% confidence interval [CI] 1.07-1.47, p = 0.005) and high-density lipoprotein cholesterol (HDL-C) levels (OR 0.93, 95% CI 0.89-0.98, p = 0.008) showed causal relationships with the risk of IA. Four lipid metabolic traits showed a causal relationship with the risk of IA (p < 0.0002). As confirmed by drug target MR, the causal relationship between the HMGCR target and IA, HMGCR target and subarachnoid hemorrhage (SAH), ANGPTL3 target and SAH, CETP target, and SAH remained statistically significant after multiple adjustments (p < 0.005). Additionally, phenome-wide MR did not identify other diseases linked to the significant lipid-lowering agent (p < 6.39 x 10(-5)). Discussion and conclusion: This study not only supports that serum lipids (TG and HDL-C) are associated with IA but also confirms the positive effect and absence of safety concerns of intervening HMGCR, ANGPTL3, and CETP targets in IA and its subtypes, opening new avenues for IA treatment.
引用
收藏
页数:12
相关论文
共 13 条
  • [1] Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis
    Chen, Lanlan
    Qiu, Wei
    Sun, Xiaodong
    Gao, Menghan
    Zhao, Yuexuan
    Li, Mingyue
    Fan, Zhongqi
    Lv, Guoyue
    [J]. GUT, 2024, 73 (03) : 521 - 532
  • [2] Effects of blood lipids and lipid-modifying drugs on intracranial aneurysms
    Zhang, Baorui
    Dong, Siyuan
    Miao, Yan
    Song, Guangrong
    Yuan, Fei
    Liu, Lang
    Xia, Saide
    Qin, Yongkai
    Huo, Xiaochuan
    Wu, Zhongxue
    Miao, Zhongrong
    Mo, Dapeng
    Liu, Aihua
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (10) : 2967 - 2975
  • [3] Genetic association of serum lipids and lipid-modifying targets with endometriosis: Trans-ethnic Mendelian-randomization and mediation analysis
    Zhang, Hongling
    Fan, Yawei
    Li, Huijun
    Feng, Xiaoqing
    Yue, Daoyuan
    [J]. PLOS ONE, 2024, 19 (05):
  • [4] Identification of lipid-modifying drug targets for autoimmune diseases: insights from drug target mendelian randomization
    Hu, Xiao
    Zhang, Peng
    Gao, Yuan
    Ding, Wen-Wen
    Cheng, Xue-Er
    Shi, Qian-Qian
    Li, Sheng
    Zhu, Yan-Yu
    Pan, Hai-Feng
    Wang, Peng
    [J]. LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [5] Associations of lipids and lipid-modifying drug target genes with atrial fibrillation risk based on genomic data
    Tao, Yuhang
    Wang, Yuxing
    Yin, Yongkun
    Zhang, Kai
    Gong, Yingchao
    Ying, Hangying
    Jiang, Ruhong
    [J]. LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [6] Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    Walldius, G
    Jungner, I
    [J]. JOURNAL OF INTERNAL MEDICINE, 2004, 255 (02) : 188 - 205
  • [7] Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments
    Yang, Ye Seul
    Lee, Seo Young
    Kim, Jung-Sun
    Choi, Kyung Mook
    Lee, Kang Wook
    Lee, Sang-Chol
    Cho, Jung Rae
    Oh, Seung-Jin
    Kim, Ji-Hyun
    Choi, Sung Hee
    [J]. ENDOCRINOLOGY AND METABOLISM, 2020, 35 (02) : 367 - 376
  • [8] Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
    Tan, Zilong
    Hong, Jing
    Sun, Aochuan
    Ding, Mengdi
    Shen, Jianwu
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [9] LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins
    Vakkilainen, J
    Jauhiainen, M
    Ylitalo, K
    Nuotio, IO
    Viikari, JSA
    Ehnholm, C
    Taskinen, MR
    [J]. JOURNAL OF LIPID RESEARCH, 2002, 43 (04) : 598 - 603
  • [10] Genomics of Lipid Metabolism: Identifying Novel Causal Pathways and New Therapeutic Targets for Reducing risk of Coronary Heart Disease
    Harshfield, Eric L.
    Stacey, David
    Paul, Dirk S.
    Koulman, Albert
    Wood, Angela M.
    Butterworth, Adam S.
    Fauman, Eric
    Griffin, Julian L.
    Danesh, John
    Saleheen, Danish
    [J]. GENETIC EPIDEMIOLOGY, 2016, 40 (07) : 614 - 615